The types of prognostic assays used to help determine candidacy for chemoimmunotherapy as frontline treatment for chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD
Advertisement
Alexey Danilov, MD, PhD, is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope
Articles by Alexey V. Danilov, MD, PhD
Drs Alexey Danilov and Anthony Mato highlight their preferences for diagnostic and prognostic testing when evaluating patients with chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.
Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the utility of rituximab biosimilars in chronic lymphocytic leukemia.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5